Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Plant Expression Systems Growing Rapidly
Use of the Technology for Vaccine Manufacture Leads the Way Toward Commercialization
- Most biotech professionals are aware that plant-based expression systems hold promise for cost-effective commercial-scale manufacture of recombinant proteins. But relatively few realize how near commercialization many of these are. With truly global, one-billion-doses-per-year-scale manufacturing facilities now under construction for influenza virus and other vaccine manufacture, these products have the ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.